Generic placeholder image

Current Radiopharmaceuticals

Author(s): Nahid Ahmadi, Hassan Yousefnia*, Ali Bahrami-Samani, Samaneh Zolghadri, Behrouz Alirezapour and Fatemeh Mohammadpour Ghazi

DOI: 10.2174/1874471013666201203152941

DownloadDownload PDF Flyer Cite As
Development of 186/188Re-Chitosan as an Effective Therapeutic Agent for Rheumatoid Arthritis

Page: [154 - 160] Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Background: Rheumatoid arthritis (RA) is an inflammatory chronic disease characterized by inflammation, pain, swelling and disability, and radiosynovectomy is one of the disease treatment lines. In this study, the possibility of providing rhenium-186/rhenium-188 chitosan radiopharmaceuticals, optimization of conditions for their production and bio-distribution are reported.

Objective: In order to build perrhenic acid for labeling, natural rhenium was exposed to radiation. Radionuclidic and radiochemical purities of (186/188Re)-NaReO4 were examined by gamma spectroscopy and paper chromatography methods, respectively.

Methods: Labeling of chitosan with rhenium was done in different acidic situations. The radiochemical purity 186/188Re-chitosan was applied by radio thin layer chromatography (RTLC). Lastly, the bio-distribution of the radiolabeled chitosan was studied in various organs after intra articular injection of the complex to lab rats. Gamma spectrometry confirmed the high rhenium radionuclidic purity. Chromatography results showed that perrhenic acid was produced with purity greater than 97% and rhenium chitosan labeling was done over 98% in pH = 3. Dissection results showed a high bio-distribution of 186/188Re-chitosan after injection into the joint with no leakage to surrounding organs.

Conclusion: According to the results, there is a possibility of labeling rhenium with chitosan in very high radiochemical purity. Regarding the high retention of these radiopharmaceuticals in joints with no leakage to surrounding organs, 186/188Re-chitosan can be applied as new radiosynovectomy drugs for rheumatoid arthritis treatment.

Keywords: Rheumatoid Arthritis, radiosynovectomy, bio-distribution, rhenium-186, rhenium-188, chitosan.

Graphical Abstract

[1]
Darlington, L.G.; Stone, T.W. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br. J. Nutr., 2001, 85(3), 251-269.
[http://dx.doi.org/10.1079/BJN2000239] [PMID: 11299072]
[2]
Delbarre, F. SYNOVIORTHESIS WITH RADIOISOTOPES; Hopital Cochin: Paris, 1968.
[3]
Jacob, R.; Smith, T.; Prakasha, B.; Joannides, T. Yttrium90 synovectomy in the management of chronic knee arthritis: a single institution experience. Rheumatol. Int., 2003, 23(5), 216-220.
[http://dx.doi.org/10.1007/s00296-003-0295-2] [PMID: 14504912]
[4]
Srivastava, S.; Dadachova, E. Recent advances in radionuclide therapy.Seminars in nuclear medicine; Elsevier, 2001.
[http://dx.doi.org/10.1053/snuc.2001.27043]
[5]
Lueders, C. Die Radiosynoviorthese. Anwendung und Durchfuehrung unter besonderer Beruecksichtigung dosimetrischer Aspekte. Aktuelle Rheumatol., 1992, 17(02), 74-81.
[http://dx.doi.org/10.1055/s-2008-1047352]
[6]
Baker, W.M. Formation of synovial cysts in connection with joints. Saint Bartholomew’s Hospital Reports, 1885, 21, 177-190.
[7]
Steinbrocker, O.; Traeger, C.H.; Batterman, R.C. Therapeutic criteria in rheumatoid arthritis. J. Am. Med. Assoc., 1949, 140(8), 659-662.
[http://dx.doi.org/10.1001/jama.1949.02900430001001] [PMID: 18150288]
[8]
Ofluoglu, S.; Schwameis, E.; Zehetgruber, H.; Havlik, E.; Wanivenhaus, A.; Schweeger, I.; Weiss, K.; Sinzinger, H.; Pirich, C. Radiation synovectomy with (166)Ho-ferric hydroxide: a first experience. J. Nucl. Med., 2002, 43(11), 1489-1494.
[PMID: 12411553]
[9]
Lee, E.B.; Shin, K.C.; Lee, Y.J.; Lee, Y.J.; Cheon, G.J.; Jeong, J.M.; Son, M.W.; Song, Y.W. 188Re-tin-colloid as a new therapeutic agent for rheumatoid arthritis. Nucl. Med. Commun., 2003, 24(6), 689-696.
[http://dx.doi.org/10.1097/00006231-200306000-00012] [PMID: 12766606]
[10]
Zolghadri, S. PRODUCTION AND QUALITY CONTROL OF 166HO-CHITOSANFOR THERAPEUTIC APPLICATIONS. 2010.
[11]
Shin, B.C.; Park, K.B.; Jang, B.S.; Lim, S.M.; Shim, C.K. Preparation of 153Sm-chitosan complex for radiation synovectomy. Nucl. Med. Biol., 2001, 28(6), 719-725.
[http://dx.doi.org/10.1016/S0969-8051(00)00211-0] [PMID: 11518654]
[12]
BAHRAMI, S.A Development of Sm-153 chitosan for radiosynovectomy. 2010.
[13]
Zolghadri, S. Development of 90 Y-chitosan as a new agent for radiosynovectomy. J. Radioanal. Nucl. Chem., 2015, 306(1), 47-55.
[http://dx.doi.org/10.1007/s10967-015-4087-4]
[14]
Schneider, P.; Farahati, J.; Reiners, C. Radiosynovectomy in rheumatology, orthopedics, and hemophilia. J. Nucl. Med., 2005, 46(Suppl. 1), 48S-54S.
[PMID: 15653651]